|28.83|| -0.28 / -0.96%|
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other. The Diagnostics segment engages in the provision of testing that is designed to assess the risk for developing disease later in life of the patient, identify the likelihood of responding to drug therapy and guide the dosing to ensure optimal treatment, or assess a the disease progression and disease recurrence of the patient. The Other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.
|Mark C. Capone||President, Chief Executive Officer & Director|
|Gary A. King||Executive Vice President-International Operations|
|R. Bryan Riggsbee||Chief Financial Officer, Treasurer & Executive VP|
|Robert Gardner Harrison||Chief Information Officer|
|Jerry S. Lanchbury||Chief Scientific Officer|